pros and cons of glp-1 drugs Compounded" | Health Communication Research Laboratory Who should take them? Pros

In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo

Here, we provide a comprehensive review of the therapeutic potential of incretin mimetics and insulin in AD and PD.

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

This paper reviews the physiological, pharmacologic, and clinical foundations linking GLP-1 RA therapy to reproductive outcomes

Moreover, in collaboration with the CNRS (National Center for Scientific Research), we have developed a specific analytical method based on stable isotope measurement